Association between antiseizure medications and thrombocytopenia: A retrospective pharmacovigilance study using the US FAERS, Japanese JADER, and Canadian CVARD databases

Thrombocytopenia is a clinically important hematological adverse event associated with several antiseizure medications (ASMs), but comparative real-world evidence across individual drugs and pharmacovigilance databases remains limited. We conducted a retrospective pharmacovigilance study using the US Food and Drug Administration Adverse Event Reporting System (FAERS) from Q1 2004 to Q2 2025, with supportive cross-database comparisons using the Japanese adverse drug event report database and the Canada vigilance adverse reaction database from January 2004 to June 2025. Thrombocytopenia events were identified using the narrow Standardized Medical Dictionary for Regulatory Activities Query "hematopoietic thrombocytopenia." Disproportionality was assessed using the reporting odds ratio and Bayesian confidence propagation neural network, and subgroup, time-to-onset, and univariable logistic regression analyses of reported fatal outcomes were also performed. In FAERS, 4835 reports with ASMs designated as primary suspect drugs were identified, corresponding to 4900 thrombocytopenia events. Positive disproportionality signals were detected for valproic acid, levetiracetam, and carbamazepine. Adults aged ≥65 years had the shortest median time to onset (14 days), and reports with serious outcomes had an earlier onset than reports without a recorded serious outcome (13 vs 29 days). Based on the reporting odds ratio criterion, valproic acid showed positive reporting signals in all 3 databases, whereas levetiracetam showed signals in FAERS and Canada Vigilance Adverse Reaction Database and carbamazepine in FAERS and Japanese adverse drug event report. Overall, this study identified drug-specific thrombocytopenia reporting signals and earlier onset patterns among older adults and reports with serious outcomes. These hypothesis-generating findings warrant further epidemiological evaluation and may inform studies of risk-adapted monitoring; they do not establish incidence, comparative safety, or causality.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-13
DOI
https://doi.org/10.1097/md.0000000000051500
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association between antiseizure medications and thrombocytopenia: A retrospective pharmacovigilance study using the US FAERS, Japanese JADER, and Canadian CVARD databases

Bao-Fen Jin, Lingyan Yu, Ru-Meng Zhang, Zhi-Kai Mai et al.
1 links
Medicine
Pharmacovigilance and Adverse Drug Reactions
article

Association between antiseizure medications and thrombocytopenia: A retrospective pharmacovigilance study using the US FAERS, Japanese JADER, and Canadian CVARD databases

Bao-Fen Jin, Lingyan Yu, Ru-Meng Zhang, Zhi-Kai Mai, Pei-Jin Zhao, Jie Huang
article en

Abstract

Thrombocytopenia is a clinically important hematological adverse event associated with several antiseizure medications (ASMs), but comparative real-world evidence across individual drugs and pharmacovigilance databases remains limited. We conducted a retrospective pharmacovigilance study using the US Food and Drug Administration Adverse Event Reporting System (FAERS) from Q1 2004 to Q2 2025, with supportive cross-database comparisons using the Japanese adverse drug event report database and the Canada vigilance adverse reaction database from January 2004 to June 2025. Thrombocytopenia events were identified using the narrow Standardized Medical Dictionary for Regulatory Activities Query "hematopoietic thrombocytopenia." Disproportionality was assessed using the reporting odds ratio and Bayesian confidence propagation neural network, and subgroup, time-to-onset, and univariable logistic regression analyses of reported fatal outcomes were also performed. In FAERS, 4835 reports with ASMs designated as primary suspect drugs were identified, corresponding to 4900 thrombocytopenia events. Positive disproportionality signals were detected for valproic acid, levetiracetam, and carbamazepine. Adults aged ≥65 years had the shortest median time to onset (14 days), and reports with serious outcomes had an earlier onset than reports without a recorded serious outcome (13 vs 29 days). Based on the reporting odds ratio criterion, valproic acid showed positive reporting signals in all 3 databases, whereas levetiracetam showed signals in FAERS and Canada Vigilance Adverse Reaction Database and carbamazepine in FAERS and Japanese adverse drug event report. Overall, this study identified drug-specific thrombocytopenia reporting signals and earlier onset patterns among older adults and reports with serious outcomes. These hypothesis-generating findings warrant further epidemiological evaluation and may inform studies of risk-adapted monitoring; they do not establish incidence, comparative safety, or causality.

MedicineVol. 105(46)
Shenzhen Maternity and Child Healthcare Hospital (CN), Xuzhou Central Hospital (CN), Shenzhen Bao'an District People's Hospital (CN), Second Affiliated Hospital of Zhejiang University (CN), Zhejiang University (CN), South China University of Technology (CN)
Good health and well-being
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon